好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Genetic Variants in Acetylcholine Processing and Significant Improvement with Pyridostigmine in a Patient with Postural Orthostatic Tachycardia Syndrome.
Autonomic Disorders
P10 - Poster Session 10 (8:00 AM-9:00 AM)
7-010

To describe genetic variants in acetylcholine processing found in a patient with postural orthostatic tachycardia syndrome (POTS) and positive response to pyridostigmine

Postural orthostatic tachycardia syndrome (POTS) is a common autonomic disorder of heterogeneous pathophysiology involving relative sympathetic overactivity and/or parasympathetic hypofunction. POTS is characterized by exaggerated postural tachycardia in the absence of orthostatic hypotension, orthostatic intolerance and other cardiovascular and neurologic features.

Case Report

We report a 30-year-old woman with POTS who experienced significant improvement with pyridostigmine. The whole genome sequencing demonstrated four single nucleotide polymorphisms - AchE,  BChE, PEMT and CHDH - variants involved in acetylcholine processing that may have led to acetylcholine deficiency and resultant parasympathetic hypofunction with relative sympathetic hyperactivity in this patient. Her Composite Autonomic Symptom Score-31 (COMPASS-31) after initiation of pyridostigmine decreased from 56.15 pre-treatment to 32 post-treatment, which indicated a 43% improvement in autonomic symptom burden, while her step count increased from an average of 4000 steps pre- to 7500 steps post-treatment with pyridostigmine.

We conclude that genetic variants in acetylcholine processing may result in acetylcholine deficiency state and may represent one of many pathophysiologic mechanisms of POTS. Whole genome sequencing and validated genetic tests for these and other genetic variants may be valuable diagnostic tools in delineating specific pathophysiology, POTS phenotypes and personalized treatment approaches.

Authors/Disclosures
Karen Stephenson
PRESENTER
Ms. Stephenson has nothing to disclose.
Amy M. Foster Miss Foster has nothing to disclose.
Svetlana Blitshteyn, MD, FAAN (Dysautonomia Clinic) Dr. Blitshteyn has received personal compensation in the range of $500-$4,999 for serving as a Consultant for CSL Behring. Dr. Blitshteyn has received publishing royalties from a publication relating to health care. Dr. Blitshteyn has received personal compensation in the range of $500-$4,999 for serving as a Healthcare Expert with Agency for Healthcare Quality and Research, US Health and Human Services.